First Multicenter, Randomized Phase 3 Study in Patients (Pts) with Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (Lumiere trial; NCT01482962)
Owen A. O’Connor(Virginia Cancer Institute), Andrei R. Shustov(Seattle Cancer Care Alliance), Francesco d’Amore(Aarhus University), Josep Maria Roncero Vidal, Judit Demeter(Semmelweis University), John P. Leonard(New York University), Claudio Dansky Ullmann(Multimeric Biotherapeutics (United States)), Francine M. Foss(Yale Cancer Center), Radhakrishnan Ramchandren(The Christie NHS Foundation Trust), E. Jane Leonard(Millennium Engineering and Integration (United States)), Judith Trotman(The University of Sydney), Eric D. Jacobsen(Dana-Farber Cancer Institute), Muhıt Özcan(Ankara University), Tamás Masszi, JungAh Jung(Takeda (United States)), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Hua Liu(Millennium Engineering and Integration (United States)), Xiaofei Zhou(Takeda (United States)), Won-Seog Kim(Samsung Medical Center), Juliana Pereira(Universidade de São Paulo), Carlos Chiattone(Hospital Samaritano de São Paulo)
Cited by 24
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k